The FIRST registry: Comparison of anticoagulant treatment in patients with atrial fibrillation
EUROPEAN HEART JOURNAL(2014)
Abstract
Aim: The FIRST registry aimed to compare patients with atrial
fibrillation treated with dabigatran or warfarin. Methods: The
study was performed in 10 centres in the Czech Republic.
Results: Upon enrolment, 33.2% and 35.6% of patients
respectively showed sinus rhythm. The last dose of warfarin
before changing to dabigatran was higher than the maintenance
dose 6.4 ± 4.3 mg vs. 4.6 ± 3.2 mg (p < 0.001). The patients
did not differ in the CHA2DS2-VASc score. The principal
difference was in the HAS BLED score: 55.3% of patients treated
with dabigatran demonstrated a score of three or more while
only 33.5% of those treated with warfarin did (p < 0.001). In
14.7% of patients treated with dabigatran, serious bleeding was
observed during the previous treatment with warfarin. In
patients treated with warfarin serious bleeding occurred in
2.0%. The most frequent reason (56.6%) for changing over to
dabigatran was the impossibility to maintain INR within the
therapeutic range. Conclusion: Patients are transferred from
warfarin to dabigatran in particular due to the impossibility
to maintain INR within the therapeutic range, and these are
more frequently patients with a higher bleeding risk.
MoreTranslated text
Key words
risk
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined